cat-2054
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02374047)
Timeline
Indications
Studied for
Mechanism of action
SREBF1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cat-2054
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02608697 | Phase 2 | Oct 1, 2015 | Catabasis |
| NCT02374047 | Phase 1 | Jan 1, 2015 | Catabasis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catabasis | For profit | 2 | 2 | 2 | 2015 |
1 organizations
Page 1 / 1